pomaglumetad
Pomaglumetad (LY-404,039) is an amino acid analog drug that acts as a highly selective agonist for the metabotropic glutamate receptor group II subtypes mGluR2 and mGluR3. Pharmacological research has focused on its potential antipsychotic and anxiolytic effects. Pomaglumetad is intended as a treatment for schizophrenia and other psychotic and anxiety disorders by modulating glutamatergic activity and reducing presynaptic release of glutamate at synapses in limbic and forebrain areas relevant to these disorders. Human studies investigating therapeutic use of pomaglumetad have focused on the prodrug LY-2140023, a methionine amide of pomaglumetad (also called pomaglumetad methionil) since pomaglumetad exhibits low oral absorption and bioavailability in humans. — Wikipedia
Clinical trial activity
24 trials · 6 clinical orgs · 0 marketing orgs
Earliest trial started Aug 1, 2005 (NCT00149292)
Timeline
Indications
Mechanism of action
GRM3 agonist
Inactive prodrug of LY404039. Eli Lilly Discontinueddevelopment, a Ph1 study sponsored by New York University School of Medicine is recruiting patients.
GRM2 agonist
Inactive prodrug of LY404039. Eli Lilly Discontinueddevelopment, a Ph1 study sponsored by New York University School of Medicine is recruiting patients.
Chemistry & pharmacology
SMILES
CSCC[C@H](N)C(=O)N[C@@]1(C(=O)O)CS(=O)(=O)[C@H]2[C@H](C(=O)O)[C@H]21.O- Mol. weight
- 384.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPomaglumetad ↗
- ChEMBLCHEMBL2110730 ↗
- ChEMBLCHEMBL2105707 ↗
- WikipediaLY-404,039 ↗
Also known as
- ly2140023
- ly2140023
- ly2140023
- ly2140023
- ly 2140023
- ly-2140023
- ly-2140023
- ly-2140023
- ly2140023 monohydrate
- pomaglumetad
- pomaglumetad
- pomaglumetad methionil
- pomaglumetad methionil
- pomaglumetad methionil
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03321617 | Phase 1 | Apr 17, 2018 | Columbia University, National Institute of Mental Health (NIMH) |
| NCT03106571 | Phase 1 | May 1, 2017 | National Institute on Drug Abuse (NIDA), University of California, Los Angeles |
| NCT02919774 | Phase 1 | Oct 1, 2016 | Columbia University, National Institute of Mental Health (NIMH) |
| NCT02234687 | N/A | Sep 1, 2014 | New York University |
| NCT01659177 | Phase 1 | Aug 1, 2012 | Eli Lilly |
| NCT01637142 | Phase 1 | Jul 1, 2012 | Eli Lilly |
| NCT01606436 | Phase 1 | Jun 1, 2012 | Eli Lilly |
| NCT01609218 | Phase 1 | May 1, 2012 | Eli Lilly |
| NCT01591330 | Phase 1 | Apr 1, 2012 | Eli Lilly |
| NCT01524237 | Phase 1 | Apr 1, 2012 | Eli Lilly |
| NCT01487083 | Phase 3 | Dec 1, 2011 | Eli Lilly |
| NCT01475136 | Phase 1 | Nov 1, 2011 | Eli Lilly |
| NCT01452919 | Phase 3 | Nov 1, 2011 | Eli Lilly |
| NCT01440478 | Phase 1 | Sep 1, 2011 | Eli Lilly |
| NCT01354353 | Phase 1 | May 1, 2011 | Eli Lilly |
| NCT01328093 | Phase 3 | Apr 1, 2011 | Eli Lilly |
| NCT01307800 | Phase 3 | Mar 1, 2011 | Eli Lilly |
| NCT01129674 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2010 | Eli Lilly |
| NCT01125358 | Phase 2 | May 1, 2010 | Eli Lilly |
| NCT01086748 | Phase 2 | Mar 1, 2010 | Eli Lilly |
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 20 | 20 | 3 | 2005 |
| Columbia University | Academic/Hospital | 2 | 2 | 1 | 2016 |
| National Institute of Mental Health (NIMH) | Government | 2 | 0 | 1 | 2016 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2017 |
| New York University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2017 |